# Case-To-Cure Master Completion Audit v0

Stewarded by [frg.earth](https://frg.earth/).

- disease program: `multiple-myeloma`
- artifact id: `multiple-myeloma-case-to-cure-master-completion-audit-v0`
- ORP item: `case-to-cure-master-completion-audit-v0`
- audit status: public-safe adaptive scope complete; next work is human-gated
- claim level: open-question
- clinical boundary: research-use-only, not medical advice
- data boundary: public artifacts and synthetic fixtures only; no real case
  data, identifiers, raw records, person-linked dates, private correspondence,
  private reviewer comments, or patient-specific outputs
- completion boundary: public-safe autonomous case-to-cure backlog only; not
  scientific completion, clinical completion, expert-review completion,
  private-lab readiness, publication approval, release approval, or a cure claim
- last reviewed: `2026-04-16`

## Purpose

This audit inspects the adaptive multiple myeloma case-to-cure backlog after
the synthetic end-to-end dry run.

It decides whether the current public-safe autonomous scope is complete,
safely blocked, or ready for another named public phase.

It does not review private lab records, real cases, expert correspondence,
clinical decisions, sponsor decisions, legal decisions, regulatory decisions,
publication decisions, or release decisions.

## Audit Decision

Decision: `public-safe-adaptive-scope-complete-human-gated`.

Meaning:

- the current `case-to-cure-master-backlog-v0` public-safe autonomous queue has
  a first useful artifact, gate, contract, dry run, or handoff for each named
  item from loop governor through this audit
- the remaining work is not a public autonomous task until a human selects a
  new named phase or clears a named gate
- ORP should record a blocked next item rather than inventing another sibling
  artifact by momentum

This decision does not mean that multiple myeloma research is complete, that
any artifact is expert-reviewed, that any artifact is clinical-review-ready,
that any case can be processed publicly, that publication is authorized, or
that a cure or vaccine has been found.

## Inputs Audited

| Input | Audit Use |
| --- | --- |
| [Case-To-Cure Adaptive Master Plan v0](case-to-cure-adaptive-master-plan-v0.md) | Canonical durable loop and backlog definition. |
| [Frontier Roadmap v0](frontier-roadmap-v0.md) | Public frontier lanes, active phase, and definition-of-complete boundary. |
| [Public Roadmap v0](public-roadmap-v0.md) | Public task posture and immediate queue state. |
| [Public Inventory v0](public-inventory-v0.md) | Current artifact surface, readiness answers, and navigation map. |
| [Case-To-Cure Pipeline Blueprint v0](case-to-cure-pipeline-blueprint-v0.md) | Stage sequence, gates, private/public zones, and remaining blockers. |
| [Case-To-Cure Stage Validator And Owner Map v0](case-to-cure-stage-validator-map-v0.md) | Stage owner artifacts, validators or gates, blockers, and allowed successors. |
| [End-To-End Synthetic Case Dry Run v0](end-to-end-synthetic-case-dry-run-v0.md) | Synthetic proof surface for success, omit, refusal, and blocker paths. |
| [Case-To-Public Learning Extraction Gate v0](case-to-public-learning-extraction-gate-v0.md) | Privacy, aggregation, source-context, review, and publication-gate envelope. |
| [Expert Validation Loop v0](reviews/expert-validation-loop-v0.md) | Public disposition-loop fields and expert-review-needed boundaries. |
| [Public Artifact Catalog v0](../../artifacts/public-artifact-catalog-v0.md) | Metadata-backed artifact coverage and navigation. |
| [ORP Frontier State](../../orp/frontier/state.json) | Live active phase before the audit. |
| [ORP Additional Items](../../orp/frontier/additional-items.json) | Durable backlog item statuses and next-state queue. |
| [ORP Version Stack](../../orp/frontier/version-stack.json) | Active version, milestone, and phase state. |
| [Private-To-Public Workflow](../../docs/private-to-public-workflow.md) | Public release and private-to-public boundary. |
| [Public Safety](../../governance/PUBLIC_SAFETY.md) | Repository-wide clinical and data-safety constraints. |

## Completion Matrix

| Public-Safe Requirement | Audit Status | Public Evidence | Residual Boundary |
| --- | --- | --- | --- |
| The adaptive loop governor prevents stopping at narrow subphase completion. | Complete. | [Case-To-Cure Loop Governor Handoff v0](case-to-cure-loop-governor-handoff-v0.md). | Future work still needs a named phase or explicit blocker. |
| Private intake shape is represented without collecting real data. | Complete. | [Private Intake Schema Contract v0](case-intake/private-intake-schema-contract-v0.md), static prototype plan, projection checklist, projection validator, and consent/privacy/security/retention gate. | Real intake, consent, storage, security, emergency handling, and clinician review remain human-gated. |
| Public projection is fail-closed for no-PHI and no-advice behavior. | Complete. | [Caregiver Intake Public Projection Validator v0](case-intake/caregiver-intake-public-projection-validator-v0.md). | No public real-data upload or public case submission is authorized. |
| Case features, measurements, exposure timeline, and molecular or immune context have public-safe contracts. | Complete. | Case-feature, measurement, therapy-exposure, and molecular-immune contracts. | Real values, reports, exact dates, and actionability interpretation remain private-lab or clinical gates. |
| Evidence retrieval has a public-source-only packet shape. | Complete. | [Evidence Retrieval Packet v0](evidence-retrieval-packet-v0.md). | Retrieval is not source completeness, evidence grading, patient matching, or trial matching. |
| Trial and therapy landscape context is non-advisory. | Complete. | [Trial Therapy Landscape Non-Advice Gate v0](therapy-landscapes/trial-therapy-landscape-non-advice-gate-v0.md). | Availability, eligibility, sequencing, access, urgency, and ranking remain blocked. |
| Candidate hypotheses are review questions, not options. | Complete. | [Candidate Hypothesis Review Question Set v0](reviews/candidate-hypothesis-review-question-set-v0.md). | No candidate option, recommendation, score, ranking, or patient-action output is authorized. |
| Multidisciplinary review packet routing is bounded. | Complete. | [Multidisciplinary Review Packet Builder v0](reviews/multidisciplinary-review-packet-builder-v0.md). | Packet assembly, generated biomedical prose, publication output, and clinical decisions remain blocked. |
| Expert validation updates can recur only as public-safe dispositions. | Complete. | [Expert Validation Loop v0](reviews/expert-validation-loop-v0.md), issue index, outreach map, and response ledger. | No outreach, private correspondence, unpublished comments, or expert-review substitution is authorized. |
| Case-to-public learning extraction is gated. | Complete. | [Case-To-Public Learning Extraction Gate v0](case-to-public-learning-extraction-gate-v0.md). | Any real case-derived public learning requires privacy, aggregation, source, expert, legal, regulatory, publication, and human review gates. |
| A synthetic-only route table exercises the full path. | Complete. | [End-To-End Synthetic Case Dry Run v0](end-to-end-synthetic-case-dry-run-v0.md). | Synthetic dry-run success does not authorize real case processing, publication, or clinical use. |
| Catalogs, README navigation, and ORP state name the current result. | Complete after this audit is cataloged and ORP is updated. | This audit, catalog entries, README links, and ORP blocker state. | Re-run validation before release or future edits. |
| Remaining work is explicitly gated. | Complete for this public-safe backlog. | Human-gate table below and ORP blocked next item. | Gates remain closed until a qualified human or future named phase resolves them. |

## Remaining Human Gates

| Gate Class | What It Covers | Why It Blocks Autonomous Public Work |
| --- | --- | --- |
| `expert-review-needed` | Claim language, MRD/endpoint wording, evidence gaps, mechanism interpretation, and issue #22 through #34 dispositions. | Public artifacts cannot substitute for expert validation or copy private expert correspondence. |
| `private-lab-needed` | Real intake, real records, normalized feature values, private evidence packets, reviewer workspaces, and private case review. | Public repo cannot receive, process, store, summarize, or expose real case material. |
| `clinical-team-needed` | Diagnosis, prognosis, treatment, trial, expanded-access, monitoring, urgency, safety-management, eligibility, or action-path decisions. | Public artifacts cannot provide clinical guidance or patient-specific interpretation. |
| `legal-needed` | Privacy basis, de-identification sufficiency, consent language, retention policy, data rights, and release constraints. | Autonomous public work cannot make legal or privacy determinations. |
| `regulatory-needed` | Institutional, ethics, sponsor, site, regulated-tool, or clinical-research pathway decisions. | These decisions require accountable human or institutional review. |
| `publication-gate-needed` | Any public case-derived learning, aggregate update, claim release, case report, or external publication. | Public release requires human authorization and review. |
| `human-review-needed` | Protected-branch review, new named phase selection, publication readiness, or maintainer approval. | ORP should not invent the next phase without human direction once the public-safe backlog is closed. |

## Not Selected As Next Autonomous Work

This audit does not select:

- real case intake, public case upload, or private workspace implementation
- de-identification automation, case extraction, case summaries, or case
  reports
- generated evidence claims, generated review packets, generated patient
  outputs, generated publication text, or generated biomedical prose
- candidate scoring, target prioritization, therapy comparison, trial matching,
  eligibility inference, access guidance, sequencing, ranking, or
  recommendation behavior
- outreach, private expert-response intake, or publication of unpublished
  correspondence
- protected-branch release, external publication, sponsor or site contact,
  legal review, regulatory review, clinical review, or treating-team decisions

## What This Step Revealed

The durable adaptive backlog has reached its intended public-safe endpoint:
the repo now has public boundaries for intake, projection, consent/privacy,
normalization, evidence retrieval, landscape context, candidate-question
review, packet routing, expert-validation dispositions, learning extraction,
publication gating, and a synthetic end-to-end route table.

The next useful action is not another autonomous artifact in the current
case-to-cure backlog. The next action is a human gate: either choose a new
named public-safe phase or clear one of the named expert, private-lab,
clinical, legal, regulatory, publication, or human-review gates.

## Handoff State

`case-to-cure-master-completion-audit-v0` is complete after this artifact is
cataloged, navigation is wired, ORP records the blocked next item, and
validation passes.

ORP should activate:

`case-to-cure-public-scope-human-gate-blocker-v0`

That blocked item means no further autonomous public-safe case-to-cure backlog
item is ready without human selection of a new phase or human clearance of a
named gate.

## Public Safety Check

- No patient-identifying data.
- No real case data.
- No private records, raw records, images, notes, exact person-linked dates,
  raw assay values, therapy histories, molecular reports, pathology reports,
  flow reports, genomics reports, clinician names, site names tied to a
  person, sponsor contacts, contact details, private paths, private prompts,
  private case IDs, or re-identification keys.
- No private correspondence, unpublished expert comments, reviewer
  deliberation, private permission context, private reviewer identities, or
  private contact details.
- No generated biomedical claims, generated case summaries, generated review
  packets, public case reports, case-derived claims, or publication workflow.
- No patient-specific diagnosis, prognosis, treatment, trial, eligibility,
  availability, access, expanded-access, monitoring, urgency,
  safety-management, referral, publication, or candidate-option guidance.
- No patient matching, trial matching, target actionability, source ranking,
  evidence ranking, target ranking, mechanism ranking, product ranking,
  therapy ranking, trial ranking, option ranking, comparison, prioritization,
  recommendation, sequencing, option selection, publication authorization,
  release authorization, or clinical decision.
- No cure or vaccine claim.

## Limitations

- This is a public completion audit, not a scientific review.
- This is not expert review.
- This is not clinical review.
- This is not legal review.
- This is not regulatory review.
- This is not privacy review.
- This is not publication review.
- This is not release review.
- This does not prove source coverage is comprehensive.
- This does not grade evidence quality.
- This does not validate real case intake, de-identification, normalization,
  evidence retrieval, expert review, multidisciplinary review, public learning
  extraction, or publication.
- This does not inspect private lab records, private correspondence, expert
  replies, or real case data.
- This does not authorize a live backend, public intake form, upload path,
  private workspace, reviewer workspace, or publication workflow.
- This does not authorize generated claims, generated packet content,
  generated case summaries, generated publication text, or generated
  patient-facing outputs.
- This does not authorize diagnosis, prognosis, treatment advice, trial
  advice, eligibility guidance, availability guidance, expanded-access
  guidance, access guidance, monitoring guidance, urgency guidance,
  safety-management guidance, or clinical decisions.
- This does not authorize patient matching, trial matching, target
  actionability, evidence ranking, therapy ranking, product ranking, trial
  ranking, option ranking, comparison, prioritization, recommendation, or
  sequencing.
- This does not authorize outreach, copying private correspondence, publishing
  unpublished reviewer comments, or declaring expert consensus.
- This does not authorize protected-branch release, external publication,
  public case reporting, or case-derived public learning.
- This does not claim that multiple myeloma has been cured or that a vaccine
  has been found.
